MF Pharmacy Program

Novartis Pharmaceuticals Australia Pty Limited is pleased to be partnering with PharmaPrograms to provide community pharmacies the opportunity to participate in the MF (Myelofibrosis) Pharmacy Program. This program supports patients diagnosed with Myelofibrosis (MF) by prompting symptom review and earlier intervention, aligned with quality use of medicines principles to optimise treatment outcomes. The MF Pharmacy Program is available to adult patients on treatment for myelofibrosis.